Catalog No.
YHE75901
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Ser66-Asn252
Predicted molecular weight
23.58 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P50402
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
EMD, EDMD, STA, Emerin
Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma., PMID:40514070
Emerin is an effector of oncogenic KRAS-driven nuclear dynamics in pancreatic cancer., PMID:40493403
Comorbidities Are Associated With Unfavorable Outcome in Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Exploratory Study From the CROCTINO Cohort., PMID:40485599
Repurposing Food and Drug Administration-approved cancer therapies: exploring endocrine and targeted pathways in low-grade serous ovarian cancer treatment., PMID:40480868
Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma., PMID:40473950
Exploring research hotspots and trends in periodontal regeneration from 2000 to 2023: a bibliometric analysis., PMID:40464866
Glial Fibrillary Acidic Protein as a Marker of Disease in Relapsing Multiple Sclerosis: Post Hoc Analysis of Phase 3 Ozanimod Trials., PMID:40462564
30 years of enamel matrix derivative: Mimicking tooth development as a clinical concept., PMID:40457946
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study., PMID:40449498
Bruton Tyrosine Kinase in Lesions of Multiple Sclerosis and 3 of Its Models., PMID:40440578
Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung Cancer., PMID:40440007
Responsiveness of different MET tumour alterations to type I and type II MET inhibitors., PMID:40437874
Microtracer-Based Assessment of the Mass Balance, Pharmacokinetics, and Excretion of [14C]Berzosertib, an Intravenous ATR Inhibitor, in Patients With Advanced Solid Tumors: A Phase 1 Study., PMID:40437704
The subfornical organ is a nucleus for gut-derived T cells that regulate behaviour., PMID:40437096
Quantitative Pharmacology Methods for Bispecific T Cell Engagers., PMID:40413295
Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implications., PMID:40404205
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer., PMID:40402502
Next-generation sequencing identifies the presence of protein phosphatase 1D, PPM1D, as a potential biomarker of resistance to PARP inhibition in metastatic castration-resistant prostate cancer., PMID:40400994
Interplay between pharmacokinetics and immunogenicity of therapeutic proteins: stepwise development of a bidirectional joint pharmacokinetics-anti-drug antibodies model., PMID:40399699
Toll-like receptor 8 activation induces a neutrophil inflammatory phenotype: therapeutic implications for the utility of toll-like receptor 8 inhibition., PMID:40397760
Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study., PMID:40393235
Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial., PMID:40389374
Advancements in bladder cancer treatment: The synergy of radiation and immunotherapy., PMID:40387780
Cost-effectiveness of cetuximab-containing regimens for squamous cell carcinoma of the head and neck in Italy., PMID:40383966
BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial., PMID:40383818
The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa study., PMID:40382524
Durable T cell immunity to COVID-19 vaccines in MS patients on B cell depletion therapy., PMID:40382362
The impact of breast radiotherapy on the tumor genome and immune ecosystem., PMID:40378044
Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma., PMID:40377969
Long-Term Efficacy of Pembrolizumab and the Clinical Utility of ctDNA in Locally Advanced dMMR/MSI-H Solid Tumors., PMID:40374594
SOHO State of the Art Updates and Next Questions | CD7 CAR-T Therapy for Treating CD7-Positive Hematological Malignancies: Clinical Advances and Future Directions., PMID:40374439
The role of serum neurofilament light (sNfL) as a biomarker in multiple sclerosis: insights from a systematic review., PMID:40372550
Cyclooxygenase-1 and cyclooxygenase-2 densities measured using positron emission tomography are not altered in the brains of individuals with stable multiple sclerosis., PMID:40367389
Dampening of Microglial Activation With Nasal Foralumab Administration in Moderate Alzheimer's Disease Dementia., PMID:40359013
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial., PMID:40349714
Nuclear Deformities Minimally Affect Fiber-Type-Specific Disease Progression in Murine Models of Nuclear Envelope Myopathy., PMID:40346876
Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial., PMID:40346292
Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer., PMID:40346041
Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception., PMID:40345189
Faecal mucoprotein MUC2 is decreased in multiple sclerosis and is associated with mucin degrading bacteria., PMID:40344717
Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial., PMID:40341383
Impaired T cell and neoantigen retention in time-serial analysis of metastatic non-small cell lung cancer in patients unresponsive to TIL cell therapy., PMID:40341231
Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab., PMID:40341029
Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study., PMID:40339592
Real-world treatment and outcomes for EGFR WT advanced/metastatic non-squamous non-small cell lung cancer: pooled analysis from project LUMINATE-101., PMID:40338221
Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation., PMID:40334661
Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer: outcomes by tumor mutational burden in POSEIDON., PMID:40334315
New Frontiers in Multiple Sclerosis Treatment: From Targeting Costimulatory Molecules to Bispecific Antibodies., PMID:40332536
PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders for Treatment of Estrogen Receptor-Positive Advanced Breast Cancer., PMID:40327300
Evaluation of bone regeneration in rat calvaria using combination of enamel matrix derivate and bone graft substitute: a histological, histometric and immunohistochemical study., PMID:40323334
For research use only. Not for human or drug use.
